Study Enrollment


Your details will not be published or shared.

Clinical Trial

WO42017 - A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1 POSITIVE CERVICAL CANCER

The purpose of this study is to compare the effects, good or bad, of tiragolumab in combination with Atezolizumab versus atezolizumab alone on patients with metastatic PD-L1-positive cervical cancer that has progressed or recurred after systemic therapy and/or patients who cannot tolerate any other globallt accepted standard of care.


Eligibility Criteria

  • Subjects must have a histologically confirmed recurrent or persisitent squamous cell cacinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with systemic chemotherapy, surgery, and/or radiotherapy. Subjects must not have had treatment with investigational therapy with therapeutic intent within 28 days prior to randomization.

Contact Information

    Katie Dorr, BSN, RN

    (706) 721-3460

   kdorr@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.